{"id":49221,"date":"2022-10-05T23:01:53","date_gmt":"2022-10-05T21:01:53","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/ladrx-corporation-announces-otcqb-ticker-change-to-ladx\/"},"modified":"2022-10-05T23:01:53","modified_gmt":"2022-10-05T21:01:53","slug":"ladrx-corporation-announces-otcqb-ticker-change-to-ladx","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/ladrx-corporation-announces-otcqb-ticker-change-to-ladx\/","title":{"rendered":"LadRx Corporation Announces OTCQB Ticker Change to LADX"},"content":{"rendered":"
\n

LOS ANGELES–(BUSINESS WIRE)–LadRx Corporation (OTCQB: LADX) (\u201cLadRx\u201d or the \u201cCompany\u201d), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it is changing its OTCQB ticker symbol from CYTR to LADX effective Thursday, October 6, 2022.\n<\/p>\n

\nChief Executive Officer Stephen Snowdy, PhD commented, \u201cFollowing up on other changes we have made this year, including the change of our name to LadRx Corporation, we are updating our ticker symbol to better reflect our Company\u2019s focus and brand. Our new name and ticker highlight our unique product platform that has given rise to one clinical drug, Aldoxorubicin, and four pre-clinical therapeutics targeted against cancer, LADRs 7, 8, 9, and 10.\u201d\n<\/p>\n

\nThere is no action required by the Company\u2019s current shareholders and the change in its ticker symbol will have no effect on its corporate structure or business. LadRx\u2019s common stock will continue to be listed on the OTCQB, and the CUSIP will remain unchanged.\n<\/p>\n

\nForward-Looking Statements<\/span><\/b>\n<\/p>\n

\nThis press release may contain certain statements relating to future results which are forward-looking statements. These statements are not historical facts, but instead represent only LadRx\u2019s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of LadRx\u2019s control. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements; and other risks and uncertainties described in the most recent annual and quarterly reports filed by LadRx with the SEC, including disclosures under the heading \u201cRisk Factors\u201d, and current reports filed since the date of the LadRx\u2019s most recent annual report. All forward-looking statements are based upon information available to LadRx on the date the statements are first published. LadRx undertakes no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise.\n<\/p>\n

\nAbout LadRx<\/span><\/b>\n<\/p>\n

\nLadRx Corporation (OTCQB: LADX) is a biopharmaceutical company with expertise in discovering and developing new therapeutics principally to treat patients with cancer. LadRx\u2019s most recent advanced drug conjugate, aldoxorubicin, is an improved version of the widely used anti-cancer drug doxorubicin and has been out-licensed to ImmunityBio, Inc. In addition, LadRx\u2019s drug candidate, arimoclomol, was sold to Orphazyme A\/S in exchange for milestone payments and royalties. Orphazyme is developing arimoclomol in two indications, including Niemann-Pick disease Type C (NPC), and Gaucher disease. LadRx Corporation\u2019s website is www.ladrxcorp.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nLongacre Square Partners
\n
Greg Marose \/ Charlotte Kiaie
\n
ladrx@longacresquare.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

LOS ANGELES–(BUSINESS WIRE)–LadRx Corporation (OTCQB: LADX) (\u201cLadRx\u201d or the \u201cCompany\u201d), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it is changing its OTCQB ticker symbol from CYTR to LADX effective Thursday, October 6, 2022. Chief Executive Officer Stephen Snowdy, PhD commented, \u201cFollowing up on other changes we have made … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-49221","6":"format-standard","7":"category-industry"},"yoast_head":"\nLadRx Corporation Announces OTCQB Ticker Change to LADX - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/ladrx-corporation-announces-otcqb-ticker-change-to-ladx\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LadRx Corporation Announces OTCQB Ticker Change to LADX - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"LOS ANGELES–(BUSINESS WIRE)–LadRx Corporation (OTCQB: LADX) (\u201cLadRx\u201d or the \u201cCompany\u201d), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it is changing its OTCQB ticker symbol from CYTR to LADX effective Thursday, October 6, 2022. Chief Executive Officer Stephen Snowdy, PhD commented, \u201cFollowing up on other changes we have made ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/ladrx-corporation-announces-otcqb-ticker-change-to-ladx\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-05T21:01:53+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ladrx-corporation-announces-otcqb-ticker-change-to-ladx\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ladrx-corporation-announces-otcqb-ticker-change-to-ladx\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"LadRx Corporation Announces OTCQB Ticker Change to LADX\",\"datePublished\":\"2022-10-05T21:01:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ladrx-corporation-announces-otcqb-ticker-change-to-ladx\\\/\"},\"wordCount\":426,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ladrx-corporation-announces-otcqb-ticker-change-to-ladx\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ladrx-corporation-announces-otcqb-ticker-change-to-ladx\\\/\",\"name\":\"LadRx Corporation Announces OTCQB Ticker Change to LADX - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2022-10-05T21:01:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ladrx-corporation-announces-otcqb-ticker-change-to-ladx\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ladrx-corporation-announces-otcqb-ticker-change-to-ladx\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ladrx-corporation-announces-otcqb-ticker-change-to-ladx\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"LadRx Corporation Announces OTCQB Ticker Change to LADX\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"LadRx Corporation Announces OTCQB Ticker Change to LADX - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/ladrx-corporation-announces-otcqb-ticker-change-to-ladx\/","og_locale":"en_US","og_type":"article","og_title":"LadRx Corporation Announces OTCQB Ticker Change to LADX - Pharma Trend","og_description":"LOS ANGELES–(BUSINESS WIRE)–LadRx Corporation (OTCQB: LADX) (\u201cLadRx\u201d or the \u201cCompany\u201d), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it is changing its OTCQB ticker symbol from CYTR to LADX effective Thursday, October 6, 2022. Chief Executive Officer Stephen Snowdy, PhD commented, \u201cFollowing up on other changes we have made ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/ladrx-corporation-announces-otcqb-ticker-change-to-ladx\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-05T21:01:53+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/ladrx-corporation-announces-otcqb-ticker-change-to-ladx\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/ladrx-corporation-announces-otcqb-ticker-change-to-ladx\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"LadRx Corporation Announces OTCQB Ticker Change to LADX","datePublished":"2022-10-05T21:01:53+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/ladrx-corporation-announces-otcqb-ticker-change-to-ladx\/"},"wordCount":426,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/ladrx-corporation-announces-otcqb-ticker-change-to-ladx\/","url":"https:\/\/pharma-trend.com\/en\/ladrx-corporation-announces-otcqb-ticker-change-to-ladx\/","name":"LadRx Corporation Announces OTCQB Ticker Change to LADX - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2022-10-05T21:01:53+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/ladrx-corporation-announces-otcqb-ticker-change-to-ladx\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/ladrx-corporation-announces-otcqb-ticker-change-to-ladx\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/ladrx-corporation-announces-otcqb-ticker-change-to-ladx\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"LadRx Corporation Announces OTCQB Ticker Change to LADX"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49221","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=49221"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49221\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=49221"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=49221"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=49221"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}